**

Immutep (IMMP), a biotechnology company focused on the development of innovative cancer immunotherapies, sent ripples through the investment community with the announcement of positive initial efficacy data and continued favorable safety data for its lead drug candidate, eftilagimod alpha (efti). This exciting development significantly boosts the prospects of efti as a potential game-changer in the treatment of various cancers and underscores the company's commitment to advancing groundbreaking cancer immunotherapies. The news sent IMMP stock soaring, highlighting the market's strong belief in the potential of this novel therapeutic approach.

Positive Efficacy Data for Eftilagimod Alpha in Phase II Trial

The positive data released by Immutep focuses on the Phase II clinical trial evaluating eftilagimod alpha in combination with Merck's KEYTRUDA® (pembrolizumab) in patients with metastatic non-small cell lung cancer (NSCLC). This combination therapy targets a critical area of unmet medical need, offering potential benefits for patients with this aggressive and often-resistant cancer. The results showed statistically significant improvements in several key efficacy endpoints, fueling hopes for accelerated development and potential regulatory approval.

Key Highlights from the Phase II Data:

• Improved Objective Response Rate (ORR): The combination of efti and KEYTRUDA demonstrated a significantly improved ORR compared to KEYTRUDA alone. This represents a substantial advancement in treatment efficacy, potentially extending the lives and improving the quality of life for patients with advanced NSCLC.

• Increased Progression-Free Survival (PFS): Data also indicated an increase in PFS, a crucial marker indicating the length of time a patient lives without disease progression. This suggests that the addition of efti to the KEYTRUDA regimen can help prevent or delay cancer recurrence.

• Favorable Safety Profile: Crucially, the combination therapy maintained a favorable safety profile, with no new or unexpected safety signals observed. This is vital for any cancer treatment, ensuring that the benefits outweigh any potential side effects.

These positive results have validated Immutep's strategy and further solidified the potential of eftilagimod alpha as a valuable addition to existing cancer immunotherapy regimens. The company is now focusing on further analysis of the data and planning for the next steps in the drug's development.

Eftilagimod Alpha: A Novel Approach to Cancer Immunotherapy

Eftilagimod alpha is a LAG-3 (lymphocyte-activation gene 3) antagonist, working differently than many traditional cancer therapies. LAG-3 is a protein that can suppress the immune system's ability to attack cancer cells. By blocking LAG-3, eftilagimod alpha helps to unleash the body's natural immune response, allowing it to more effectively target and destroy cancer cells. This unique mechanism of action sets efti apart from other immunotherapies currently on the market.

How Eftilagimod Alpha Works:

• LAG-3 Inhibition: Efti directly inhibits LAG-3, a key immune checkpoint protein that suppresses T cell activation.

• Enhanced T Cell Activation: By blocking LAG-3, efti promotes the activation and proliferation of T cells, the body's primary defense against cancerous cells.

• Synergistic Effects with Checkpoint Inhibitors: The data suggests eftilagimod alpha works synergistically with checkpoint inhibitors like KEYTRUDA, leading to a more potent anti-tumor response.

This novel approach has captured the attention of investors and researchers alike, positioning Immutep as a significant player in the evolving landscape of cancer immunotherapy. The successful Phase II results reinforce the belief that eftilagimod alpha has the potential to become a key component of future cancer treatment strategies.

Implications for Investors and the Future of Immutep (IMMP)

The positive Phase II data significantly strengthens Immutep's position in the market. This success offers several key implications for investors:

• Increased Stock Value: The positive news is likely to lead to increased investor confidence, potentially driving up IMMP's stock price. The market reaction to similar announcements from other biotech companies reinforces this expectation.

• Accelerated Clinical Development: Immutep is likely to accelerate its clinical development program for eftilagimod alpha, potentially exploring additional indications and combination therapies.

• Potential for Partnerships and Acquisitions: The positive data increases the attractiveness of Immutep as a potential partner or acquisition target for larger pharmaceutical companies.

The future looks bright for Immutep. The company is actively pursuing multiple clinical trials evaluating eftilagimod alpha across different cancer types, demonstrating its commitment to broadening the drug's therapeutic potential. The success in this Phase II trial sets the stage for further pivotal clinical studies and potential regulatory submissions. The company’s continued focus on research and development, alongside its strategic partnerships, will be crucial in determining the long-term success of eftilagimod alpha and the overall growth of Immutep.

Conclusion: A Promising Future for Cancer Immunotherapy

The positive efficacy data released by Immutep represents a significant milestone in the development of eftilagimod alpha and showcases the potential of novel cancer immunotherapies. The encouraging results from the Phase II trial, combined with the favorable safety profile, point towards a promising future for this innovative therapy. The positive market reaction underscores the potential for eftilagimod alpha to revolutionize cancer treatment, offering new hope to patients battling this devastating disease. Investors will be keenly watching Immutep's next moves as it advances this potentially groundbreaking therapy through the clinical development pipeline. The long-term impact of this announcement on cancer treatment and the biotech industry is substantial and deserves close monitoring. Further updates and data from ongoing trials will be critical in shaping the future of this exciting new therapy.